Decheng Capital LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Decheng Capital LLC disclosed 27 US equity positions worth $356.5m in its Q1 2025 13F filing. The largest position was CGON at 43.8% of the reported book, followed by NUVB and AARD. Against the Q4 2024 filing, it opened 1 new position, added to 2 and reduced 8 among the top 27 holdings.
What did Decheng Capital LLC own in Q1 2025? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 43.8% | $156.0m | 6,371,669 | 0% | held |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 12.8% | $45.7m | 25,954,439 | 0% | held |
| 3 | AARD AARDVARK THERAPEUTICS INC | 8.3% | $29.4m | 3,917,299 | – | new | |
| 4 | UPB Upstream Bio Inc. | 5.6% | $20.1m | 3,285,293 | 0% | held | |
| 5 | NEWAMSTERDAM PHARMA CO NV | 4.4% | $15.8m | 770,000 | 0% | held | |
| 6 | KRYS KRYSTAL BIOTECH INC | Healthcare | 3.3% | $11.7m | 65,000 | -15% | reduced |
| 7 | RVMD REVOLUTION MEDICINES INC(NSM) | Healthcare | 2.2% | $8.0m | 226,000 | 0% | held |
| 8 | MERUS NV | 2.2% | $8.0m | 189,098 | 0% | held | |
| 9 | BYSI BeyondSpring Inc. | 2.0% | $7.0m | 4,882,651 | 0% | held | |
| 10 | MOONLAKE IMMUNOTHERAPEUTICS | 1.9% | $6.7m | 171,600 | 0% | held | |
| 11 | LYEL Lyell Immunopharma, Inc. | 1.8% | $6.4m | 11,909,341 | 0% | held | |
| 12 | RCUS Arcus Biosciences, Inc | Healthcare | 1.8% | $6.3m | 808,789 | 0% | held |
| 13 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 1.7% | $6.2m | 4,041,736 | 78% | added |
| 14 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 1.7% | $6.0m | 177,958 | 6% | added | |
| 15 | CYTK CYTOKINETICS INC | Healthcare | 1.1% | $4.0m | 100,000 | 0% | held |
| 16 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 1.0% | $3.4m | 100,000 | -35% | reduced |
| 17 | ACLXGBX ARCELLX INC | 0.9% | $3.3m | 50,000 | -41% | reduced | |
| 18 | ZNTL Zentalis Pharmaceuticals Inc. | Healthcare | 0.9% | $3.2m | 2,019,762 | -14% | reduced |
| 19 | AURA Aura Biosciences, Inc. | 0.8% | $3.0m | 515,555 | 0% | held | |
| 20 | BNTX Biontech SE-ADR | Healthcare | 0.5% | $1.8m | 20,000 | -50% | reduced |
| 21 | EQ Equillium Inc. | 0.5% | $1.7m | 4,447,308 | 0% | held | |
| 22 | FDMT 4D MOLECULAR THERAPEUTICS IN | 0.3% | $1.1m | 335,515 | -16% | reduced | |
| 23 | ILMN Illumnia, Inc. | Healthcare | 0.3% | $932.2k | 11,749 | -88% | reduced |
| 24 | PYXS Pyxis Oncology, Inc (formerly Apexigen) | 0.1% | $320.2k | 326,810 | 0% | held | |
| 25 | GRAL GRAIL INC | 0.1% | $247.3k | 9,684 | 0% | held | |
| 26 | VERA VERA THERAPEUTICS INC | Healthcare | 0.0% | $108.0k | 4,495 | -91% | reduced |
| 27 | Nuvation Bio Inc. | 0.0% | $44.0k | 646,057 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.